CA2488861A1 - Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere - Google Patents

Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere Download PDF

Info

Publication number
CA2488861A1
CA2488861A1 CA002488861A CA2488861A CA2488861A1 CA 2488861 A1 CA2488861 A1 CA 2488861A1 CA 002488861 A CA002488861 A CA 002488861A CA 2488861 A CA2488861 A CA 2488861A CA 2488861 A1 CA2488861 A1 CA 2488861A1
Authority
CA
Canada
Prior art keywords
treatment
hydroxy
group
production
iloprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002488861A
Other languages
English (en)
Inventor
Cornelia Norden
Nicolas Aigner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2488861A1 publication Critical patent/CA2488861A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation de dérivés de prostacycline disponibles par voie orale pour préparer un produit pharmaceutique pour traiter des maladies qui sont associées à des oedèmes de la moelle épinière.
CA002488861A 2002-06-06 2003-06-05 Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere Abandoned CA2488861A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10225551.2 2002-06-06
DE10225551A DE10225551A1 (de) 2002-06-06 2002-06-06 Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
PCT/EP2003/005990 WO2003103681A2 (fr) 2002-06-06 2003-06-05 Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere

Publications (1)

Publication Number Publication Date
CA2488861A1 true CA2488861A1 (fr) 2003-12-18

Family

ID=29594336

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002488861A Abandoned CA2488861A1 (fr) 2002-06-06 2003-06-05 Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere

Country Status (9)

Country Link
EP (1) EP1515728A2 (fr)
JP (1) JP2005536476A (fr)
KR (1) KR20050007591A (fr)
CN (1) CN1658882A (fr)
AU (1) AU2003236715A1 (fr)
CA (1) CA2488861A1 (fr)
DE (1) DE10225551A1 (fr)
WO (1) WO2003103681A2 (fr)
ZA (1) ZA200500097B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1993557T1 (sl) * 2006-02-03 2016-01-29 Actelion Pharmaceuticals Ltd. Nova formulacija epoprostenola in postopek izdelave le-te
TWI520740B (zh) * 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
WO2019043148A1 (fr) * 2017-08-31 2019-03-07 Charité Universitätsmedizin Berlin Immunomodulation pour la prévention d'une mauvaise cicatrisation de lésions musculo-squelettiques chez des patients fragilisés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
ES2101333T3 (es) * 1992-08-07 1997-07-01 Schering Ag Utilizacion de derivados de prostano para la preparacion de un medicamento destinado al tratamiento de la poliartritis cronica.
CA2303343C (fr) * 1997-09-16 2011-01-04 Toray Industries, Inc. Inhibiteur de la production de chemokine c-c
AU2002212996A1 (en) * 2000-09-28 2002-04-08 Non-Invasive Monitoring Systems, Inc. External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention

Also Published As

Publication number Publication date
KR20050007591A (ko) 2005-01-19
JP2005536476A (ja) 2005-12-02
WO2003103681A2 (fr) 2003-12-18
WO2003103681A3 (fr) 2004-03-25
CN1658882A (zh) 2005-08-24
EP1515728A2 (fr) 2005-03-23
AU2003236715A1 (en) 2003-12-22
ZA200500097B (en) 2006-06-28
DE10225551A1 (de) 2003-12-24

Similar Documents

Publication Publication Date Title
RU2166940C2 (ru) Способ уменьшения потерь костной ткани, способ лечения остеопороза и применение соединения
US4666897A (en) Inhibition of mammalian collagenolytic enzymes by tetracyclines
JP3623962B2 (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
CA2592086C (fr) Melange contenant un agoniste des recepteurs vanilloides et une substance inhibant la regeneration des nerfs, utilisation de ce melange pour produire un analgesique et procede d'application de cet analgesique
JPH09504543A (ja) 白内障の予防法及び予防手段
JP2005515181A (ja) 骨関節症を治療するための、ヒアルロン酸ナトリウムとコンドロイチン硫酸との混合物の使用
JP2003505422A5 (fr)
JP2004532868A5 (fr)
JPH08231387A (ja) うつ病でない雌性の哺乳動物における視床下部性無月経を処置するための医薬組成物
CA2594202A1 (fr) Utilisation de la resiniferatoxine (rtx) pour produire un agent servant a traiter des douleurs articulaires, et procede d'administration de cet agent
JP5080983B2 (ja) バニロイド受容体アゴニストをグリコースアミノグリカンまたはプロテオグリカンとともに関節痛治療のための薬剤の製造に用いることおよび前記薬剤の適用方法
GB2330307A (en) EP4 Receptor antagonists as bone resorption inhibitors
US20050101673A1 (en) Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas
CA2488861A1 (fr) Utilisation de derives de prostacycline disponibles par voie orale pour preparer un produit pharmaceutique pour traiter des maladies qui sont associees a des oedemes de la moelle epiniere
US4185108A (en) Antiosteoporotic agents
US4125621A (en) Antiosteoporotic agents
JPH0489428A (ja) 多形核白血球活性化剤
EP1080728A1 (fr) Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
JPH0222226A (ja) Ｐｇｄ類似化合物を有効成分として含有する骨疾患治療剤
CA2219354A1 (fr) Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
Herbai TREATMENT OF PROGRESSIVE SYSTEMIC SCLEROSIS WITH A SYNTHETIC WEAK ESTROGEN: CYCLOFENIL (SEXOVID®) Report of a Case
NZ308935A (en) Use of Alendronate for the prevention of osteoporosis
Stewart et al. Acquired anterior open bite and facial arthromyalgia: possible aetiology
WO2004009117A1 (fr) Agent tocolytique comprenant comme principe actif un agoniste de ep2
JPH0753388A (ja) 骨代謝改善剤

Legal Events

Date Code Title Description
FZDE Discontinued